ARTICLE | Finance
Summer sweeteners
How biotechs tapping the market are sweetening their deal terms
May 23, 2016 7:00 AM UTC
Biotechs looking to tap the markets are sweetening their deal terms with deep discounts or bells and whistles such as warrants. The goal is to entice the handful of buysiders shopping for bargains because they see little upside for the sector until after the U.S. presidential election in November.
This year, 25% of all public equity financings have included warrants, which essentially give investors the ability to buy shares on the cheap if a company's stock price rises. Last year, 18% came with warrants. ...